New Drug Treatments Revolutionize Care for Metabolic Dysfunction-Associated Steatohepatitis

The landscape of drug treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), particularly its more severe form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), is undergoing a significant transformation. Historically, management focused on lifestyle changes and addressing comorbidities like type 2 diabetes and cardiovascular risk factors. This review highlights the emergence of targeted pharmacological interventions, but a critical gap remains in determining the optimal drug combinations, prescription durations, and treatment strategies for patients with MASH-related cirrhosis.

The review identified resmetirom as the first effective and well-tolerated drug specifically marketed in the USA and Europe for MASH patients with significant liver fibrosis (F2-F3). Emerging therapies like semaglutide and other incretin receptor/glucagon receptor agonists show immense promise, primarily due to their ability to induce very significant weight loss. Semaglutide has been shown to achieve a remarkable weight reduction ranging from 10% to more than 24% of initial body weight, making it a potential cornerstone for MASLD drug management. Furthermore, semaglutide has demonstrated additional benefits, including a reduction in cardiovascular and renal events, and has received marketing approval in the USA for MASH without cirrhosis. These findings signify a major shift towards targeted pharmacological interventions for this complex liver disease.